%0 Journal Article
%A Fraile-Ribot, Pablo A.
%A Zamorano, Laura
%A Orellana, Rocio
%A Del Barrio-Tofiño, Ester
%A Sanchez-Diener, Irina
%A Cortes-Lara, Sara
%A Lopez-Causape, Carla
%A Cabot, Gabriel
%A Bou, German
%A Martinez-Martinez, Luis
%A Oliver, Antonio
%T Activity of Imipenem-Relebactam against a Large Collection of Pseudomonas aeruginosa Clinical Isolates and Isogenic β-Lactam-Resistant Mutants.
%D 2019
%U http://hdl.handle.net/10668/14708
%X Imipenem and imipenem-relebactam MICs were determined for 1,445 Pseudomonas aeruginosa clinical isolates and a large panel of isogenic mutants showing the most relevant mutation-driven β-lactam resistance mechanisms. Imipenem-relebactam showed the highest susceptibility rate (97.3%), followed by colistin and ceftolozane-tazobactam (both 94.6%). Imipenem-relebactam MICs remained ≤2 μg/ml in all 16 isogenic PAO1 mutants and in 8 pairs of extensively drug-resistant clinical strains that had developed resistance to ceftolozane-tazobactam and ceftazidime-avibactam due to mutations in OXA-10 or AmpC.
%K Pseudomonas aeruginosa
%K Antibiotic resistance
%K Extensively drug resistant
%K Imipenem-relebactam
%K Multidrug resistance
%K Whole-genome sequencing
%K β-lactam resistance mechanisms
%~